Biomark Diagnostics
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment. The last earnings update was 51 days ago. More info.
Add to Portfolio Compare Print
- Biomark Diagnostics has significant price volatility in the past 3 months.
20B Share Price and Events
7 Day Returns
1 Year Returns
20B Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Biomark Diagnostics (20B) | 18.9% | 29.4% | 109.5% | 4.8% | -48.8% | - |
| DE Biotechs | -2.4% | 1.8% | -7.7% | -10.2% | 51.2% | 10.1% |
| DE Market | 1.8% | 4.2% | 7.4% | -6% | 10.1% | 15.4% |
1 Year Return vs Industry and Market
- 20B outperformed the Biotechs industry which returned -10.2% over the past year.
- 20B outperformed the Market in Germany which returned -6% over the past year.
20B Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether Biomark Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biomark Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for Biomark Diagnostics. This is due to cash flow or dividend data being unavailable. The share price is €0.044.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Biomark Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Biomark Diagnostics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in CAD | CA$-0.01 |
| DB:20B Share Price ** | DB (2019-04-18) in EUR | €0.04 |
| DB:20B Share Price converted to CAD reporting currency | Exchange rate (EUR/ CAD) 1.506 | CA$0.07 |
| Europe Biotechs Industry PE Ratio | Median Figure of 30 Publicly-Listed Biotechs Companies | 22.44x |
| Germany Market PE Ratio | Median Figure of 422 Publicly-Listed Companies | 19.59x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Biomark Diagnostics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = DB:20B Share Price ÷ EPS (both in CAD) = 0.07 ÷ -0.01 |
-7.36x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Biomark Diagnostics is loss making, we can't compare its value to the Europe Biotechs industry average.
- Biomark Diagnostics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does
Biomark Diagnostics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -7.36x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| Europe Biotechs Industry PEG Ratio | Median Figure of 22 Publicly-Listed Biotechs Companies | 1.3x |
| Germany Market PEG Ratio | Median Figure of 270 Publicly-Listed Companies | 1.57x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Biomark Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Biomark Diagnostics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in CAD | CA$-0.02 |
| DB:20B Share Price * | DB (2019-04-18) in EUR | €0.04 |
| DB:20B Share Price converted to CAD reporting currency | Exchange rate (EUR/ CAD) 1.506 | CA$0.07 |
| Germany Biotechs Industry PB Ratio | Median Figure of 15 Publicly-Listed Biotechs Companies | 3.71x |
| Germany Market PB Ratio | Median Figure of 570 Publicly-Listed Companies | 1.84x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = DB:20B Share Price ÷ Book Value per Share (both in CAD) = 0.07 ÷ -0.02 |
-3.92x |
* Primary Listing of Biomark Diagnostics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Biomark Diagnostics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Value checks
We assess Biomark Diagnostics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Biomark Diagnostics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
20B Future Performance
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomark Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Biomark Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Biomark Diagnostics's earnings growth to the Germany market average as no estimate data is available.
- Unable to compare Biomark Diagnostics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Germany Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 47.5% |
| Germany Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 26% |
| Germany Market Earnings Growth Rate | Market Cap Weighted Average | 11.5% |
| Germany Market Revenue Growth Rate | Market Cap Weighted Average | 4.8% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | -1 | -1 | |
| 2018-09-30 | -1 | -1 | |
| 2018-06-30 | -1 | -1 | |
| 2018-03-31 | -1 | -1 | |
| 2017-12-31 | 0 | -1 | |
| 2017-09-30 | 0 | -1 | |
| 2017-06-30 | 0 | -1 | |
| 2017-03-31 | 0 | -1 | |
| 2016-12-31 | 0 | -1 | -1 |
| 2016-09-30 | 0 | 0 | -1 |
| 2016-06-30 | 0 | -1 | |
| 2016-03-31 | 0 | -1 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Biomark Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.01 |
| 2018-09-30 | -0.01 |
| 2018-06-30 | -0.01 |
| 2018-03-31 | -0.01 |
| 2017-12-31 | -0.01 |
| 2017-09-30 | -0.01 |
| 2017-06-30 | -0.01 |
| 2017-03-31 | -0.01 |
| 2016-12-31 | -0.02 |
| 2016-09-30 | -0.03 |
| 2016-06-30 | -0.03 |
| 2016-03-31 | -0.03 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Biomark Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Biomark Diagnostics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Biomark Diagnostics has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
20B Past Performance
How has Biomark Diagnostics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Biomark Diagnostics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Biomark Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Biomark Diagnostics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Biomark Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | -0.57 | 0.47 | 0.07 | |
| 2018-09-30 | -0.60 | 0.47 | 0.06 | |
| 2018-06-30 | -0.65 | 0.53 | 0.05 | |
| 2018-03-31 | -0.73 | 0.60 | 0.06 | |
| 2017-12-31 | -0.82 | 0.67 | 0.08 | |
| 2017-09-30 | -0.75 | 0.66 | 0.07 | |
| 2017-06-30 | -0.68 | 0.60 | 0.06 | |
| 2017-03-31 | -0.72 | 0.64 | 0.05 | |
| 2016-12-31 | 0.00 | -1.18 | 1.15 | -0.03 |
| 2016-09-30 | 0.00 | -1.33 | 1.19 | 0.08 |
| 2016-06-30 | -1.41 | 1.26 | 0.10 | |
| 2016-03-31 | -1.40 | 1.14 | 0.21 | |
| 2015-12-31 | 0.00 | -1.41 | 1.08 | 0.29 |
| 2015-09-30 | 0.00 | -3.20 | 1.57 | 0.36 |
| 2015-06-30 | -3.02 | 1.42 | 0.33 | |
| 2015-03-31 | -2.88 | 1.39 | 0.21 | |
| 2014-03-31 | -0.18 | 0.18 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Biomark Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Biomark Diagnostics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Biomark Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Past performance checks
We assess Biomark Diagnostics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Biomark Diagnostics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
20B Health
How is Biomark Diagnostics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Biomark Diagnostics's finances.
The net worth of a company is the difference between its assets and liabilities.
- Biomark Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Biomark Diagnostics has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Biomark Diagnostics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Biomark Diagnostics Company Filings, last reported 3 months ago.
| Date (Data in CAD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -1.10 | 1.01 | 0.06 |
| 2018-09-30 | -1.01 | 0.89 | 0.03 |
| 2018-06-30 | -0.85 | 0.86 | 0.13 |
| 2018-03-31 | -0.90 | 0.00 | 0.04 |
| 2017-12-31 | -0.80 | 0.70 | 0.12 |
| 2017-09-30 | -0.63 | 0.66 | 0.28 |
| 2017-06-30 | -0.66 | 0.78 | 0.46 |
| 2017-03-31 | -1.07 | 0.00 | 0.02 |
| 2016-12-31 | -0.84 | 0.00 | 0.00 |
| 2016-09-30 | -0.75 | 0.55 | 0.01 |
| 2016-06-30 | -0.60 | 0.43 | 0.00 |
| 2016-03-31 | -0.55 | 0.00 | 0.01 |
| 2015-12-31 | -0.51 | 0.34 | 0.00 |
| 2015-09-30 | -0.26 | 0.22 | 0.02 |
| 2015-06-30 | -0.09 | 0.14 | 0.04 |
| 2015-03-31 | 0.15 | 0.00 | 0.20 |
| 2014-03-31 | 0.09 | 0.00 | 0.09 |
- Biomark Diagnostics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Biomark Diagnostics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Biomark Diagnostics has less than a year of cash runway based on current free cash flow.
- Biomark Diagnostics has less than a year of cash runway if free cash flow continues to grow at historical rates of 25.7% each year.
Financial health checks
We assess Biomark Diagnostics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Biomark Diagnostics has a total score of 1/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
20B Dividends
What is Biomark Diagnostics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Biomark Diagnostics
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Biomark Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Biomark Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.9% |
| Germany Market Average Dividend Yield | Market Cap Weighted Average of 326 Stocks | 3% |
| Germany Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| Germany Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| Germany Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Biomark Diagnostics has not reported any payouts.
- Unable to verify if Biomark Diagnostics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Biomark Diagnostics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Biomark Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Biomark Diagnostics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
20B Management
CEO
| COMPENSATION | CA$240,000 |
| TENURE AS CEO | 4.8 years |
CEO Bio
Mr. Rashid Ahmed Bux, B.Sc., MBA, is the Founder of BioMark Technologies Inc., a bio pharm business, which has achieved Phase III status in an unprecedented 3 years and has been it Chief Executive Officer since June 19, 2014. Mr. Bux serves as Chief Executive Officer and President of Biomark Diagnostics Inc. He has more than 20 years of business management at the senior level. He was co-founder and Chief Operating Officer of Optima Health and KKT Spinecentres a developer and operator of spinal treatment centers located in Germany, China, Taiwan, UAE, Canada and India. He was President and Founder of Homeworks Inc. a subsidiary of BC Gas, the natural gas distributor in British Columbia, Canada. He servers on the board of two nternational health related companies and provides advisory services to African nations principally in East Africa. He has extensive contacts in the medical sectors on a global basis. He has been a Director of Biomark Diagnostics Inc. since June 19, 2014. He was inducted in the distinguished Phi Kappa Phi honorary for his outstanding educational achievement. He earned a Bachelor of Science in Business Administration with concentration in three areas from the Miami University in Ohio. He has the degree in Master of Business Administration from the University of Western Ontario where he earned several distinguished scholarships. He was a student at Nairobi University prior to obtaining a scholarship to attend Miami University.
CEO Compensation
- Rashid's compensation has been consistent with company performance over the past year.
- Rashid's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the Biomark Diagnostics management team in years:
- The average tenure for the Biomark Diagnostics management team is less than 2 years, this suggests a new team.
Management Team
Rashid Bux
Founder
CA$240K
4.8 yrs
Brian Cheng
CTO & Director
Gina Huang
CFO & Project Director
1.8 yrs
Thomas Malcolm
Chief Scientific Officer
Neal Kaplan
Chief Financial Officer of US
Daniel Sitar
Principal Scientific Advisor
Abbey Abdiye
Executive Officer
CA$72K
43
1.8 yrs
Board of Directors Tenure
Average tenure of the Biomark Diagnostics board of directors in years:
- The tenure for the Biomark Diagnostics board of directors is about average.
Board of Directors
Rashid Bux
Founder
CA$240K
4.8 yrs
Brian Cheng
CTO & Director
4.6 yrs
Bram Ramjiawan
Director
4.6 yrs
Bill Good
Member of Media Advisory Board
Ian C. Smith
Director
1.4 yrs
Mike Weisfeldt
Member of Scientific Advisory board
0.4 yrs
Sandeep Singhal
Member of Scientific Advisory Board
0.5 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 07. Mar 19 | Buy | Grg Consulting Ltd. | Company | 07. Mar 19 | 07. Mar 19 | 10,000 | €0.03 | €298 | ||
| 06. Mar 19 | Buy | Grg Consulting Ltd. | Company | 05. Mar 19 | 05. Mar 19 | 10,000 | €0.03 | €298 | ||
| 04. Mar 19 | Buy | Grg Consulting Ltd. | Company | 04. Mar 19 | 04. Mar 19 | 12,000 | €0.03 | €398 | ||
| 19. Feb 19 | Buy | Grg Consulting Ltd. | Company | 19. Feb 19 | 19. Feb 19 | 3,000 | €0.03 | €100 | ||
| 18. Feb 19 | Buy | Grg Consulting Ltd. | Company | 14. Feb 19 | 14. Feb 19 | 7,000 | €0.03 | €233 | ||
| 01. Feb 19 | Buy | Grg Consulting Ltd. | Company | 31. Jan 19 | 31. Jan 19 | 30,000 | €0.03 | €896 | ||
| 01. Jan 19 | Buy | Grg Consulting Ltd. | Company | 28. Dec 18 | 28. Dec 18 | 30,000 | €0.03 | €865 | ||
| 09. Oct 18 | Buy | Grg Consulting Ltd. | Company | 05. Oct 18 | 05. Oct 18 | 500,000 | €0.07 | €33,576 | ||
| 02. Oct 18 | Buy | Grg Consulting Ltd. | Company | 01. Oct 18 | 01. Oct 18 | 30,000 | €0.03 | €1,012 | ||
Management checks
We assess Biomark Diagnostics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Biomark Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
20B News
Simply Wall St News
The Biomark Diagnostics (FRA:20B) Share Price Is Down 69% So Some Shareholders Are Wishing They Sold
Biomark Diagnostics Inc (FRA:20B) has rebounded strongly over the last week, with the share price soaring 140%. … Biomark Diagnostics hasn't yet reported any revenue yet, so it's as much a business idea as a business. … But with the share price diving 32% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed
Simply Wall St - – Full articleBiomark Diagnostics Inc (FRA:20B): How Does It Impact Your Portfolio?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … How 20B's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … However, this is the opposite to what 20B’s actual beta value suggests, which is higher stock volatility relative to the market.
Simply Wall St - – Full articleShould You Be Concerned About Biomark Diagnostics Inc's (FRA:20B) Shareholders?
This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: Institutional ownership in 20B is not at a level that would concern investors.
Simply Wall St - – Full articleWas Biomark Diagnostics Inc's (FRA:20B) Earnings Growth Better Than The Industry's?
When Biomark Diagnostics Inc's (DB:20B) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Biomark Diagnostics's average earnings over the past couple of years, and its industry performance. … See our latest analysis for Biomark Diagnostics Did 20B's recent earnings growth beat the long-term trend and the industry?
Simply Wall St - – Full article20B Company Info
Description
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Details
| Name: | Biomark Diagnostics Inc |
| 20B | |
| Exchange: | DB |
| Founded: | 2014 |
| €2,948,665 | |
| 67,015,119 | |
| Website: | http://www.biomarkdiagnostics.com |
| Address: |
Biomark Diagnostics Inc 165 – 10551 Shellbridge Way, Richmond, British Columbia, V6X 2W8, Canada |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| DB | 20B | Common Shares | Deutsche Boerse AG | DE | EUR | 26. Nov 2014 | |
| OTCPK | BMKD.F | Common Shares | Pink Sheets LLC | US | USD | 26. Nov 2014 | |
| CNSX | BUX | Common Shares | Canadian National Stock Exchange | CA | CAD | 26. Nov 2014 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/20 21:48 |
| End of day share price update: | 2019/04/18 00:00 |
| Last earnings filing: | 2019/02/28 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
